![chinabased keep linkdoc us ipotimes chinabased keep linkdoc us ipotimes](https://venturebeat.com/wp-content/uploads/2020/01/Screen-Shot-2020-01-22-at-5.47.09-AM.png)
![chinabased keep linkdoc us ipotimes chinabased keep linkdoc us ipotimes](https://www.btcethereum.com/blog/wp-content/uploads/2021/07/147606-just-hodl-bitcoin-and-ethereum-outperform-lower-risk-crypto-index-funds-728x409.jpg)
It is the first Chinese firm known to have pulled back from IPO plans since China's cybersecurity regulator toughened its approach to oversight. listing by a Chinese firm on record, after Alibaba Group Holding Ltd.’s $25 billion blockbuster debut in 2014. HONG KONG (Reuters) -Chinese medical data group LinkDoc Technology Ltd has shelved plans for an IPO in the United States due to Beijing's clampdown on overseas listings by domestic firms, according to three sources with direct knowledge of the matter. this year, according to data compiled by Bloomberg. The case examines how LinkDoc, specializing in big data and serving the vertical healthcare industry, found its own answers to these issues and, more specifically, how it identified and entered its target market segment, and. Its investors include Alibaba Health Information Technology Ltd., MBK Partners, New Enterprise Associates and Temasek Holdings Pte according to a preliminary filing.Ĭhinese companies have raised about $13 billion through first-time share sales in the U.S. LinkDoc’s IPO delay also comes as regulators in Beijing are planning rule changes that would allow them to block a Chinese. The LinkDoc Technology (hereinafter 'LinkDoc') case was compiled as one way to find answers to these questions. LinkDoc, founded in 2014, provides cancer focused health-care services built on big data and artificial intelligence, its website shows. HONG KONG Chinese medical data group LinkDoc Technology Ltd has shelved its listing in the United States to raise up to 211 million following Beijing’s clampdown on overseas listings, according to three sources with direct knowledge of the matter. We are leading oncology real world big data company from China with the vision of care data and care life. initial public offering, people familiar with the matter said, the first known company to pull out of a debut after China. The company’s listing plans come despite the U.S.
![chinabased keep linkdoc us ipotimes chinabased keep linkdoc us ipotimes](https://venturebeat.com/wp-content/uploads/2020/01/household-notes_1-e1578412570862.png)
A representative for LinkDoc declined to comment. LinkDoc Technology 859 followers on LinkedIn. For the same period, net loss attributable to LinkDoc widened to 135.4 million renminbi (21.17 million) from 61.6 million renminbi a year earlier. Reuters reported LinkDoc’s IPO halt earlier Thursday. LinkDoc’s IPO delay also comes as regulators in Beijing are planning rule changes that would allow them to block a Chinese company from listing overseas even if the unit selling shares is incorporated outside China, closing a loophole long-used by the country’s technology giants, Bloomberg News reported this week. Chinese medical data startup LinkDoc Technology is planning to raise 500 million in an initial public offering (IPO), Bloomberg reported, citing sources.